3D Microtumors Representing Ovarian Cancer Minimal Residual Disease Respond to the Fatty Acid Oxidation Inhibitor Perhexiline

    February 2025 in “ Advanced Healthcare Materials
    Xingyun Yang, Mara Artibani, Yongcheng Jin, Aneesh Aggarwal, Yujia Zhang, Sandra Muñoz-Galván, Ellina Mikhailova, Lena Rai, Nobina Mukherjee, Ravinash Krishna Kumar, Ashwag Albukhari, Shaohua Ma, Linna Zhou, Ahmed A. Ahmed, Hagan Bayley
    TLDR Perhexiline can effectively target ovarian cancer cells left after treatment.
    The study introduces a microfluidics platform for creating 3D microtumors that effectively mimic ovarian cancer minimal residual disease (MRD), offering a more accurate model than traditional 2D cultures. These microtumors replicate key features such as hypoxia and lipid metabolism, and they exhibit higher resistance to chemotherapy, reflecting the drug-resistant nature of MRD. The study demonstrates that the fatty acid oxidation inhibitor Perhexiline significantly reduces MRD cell viability in these 3D models, highlighting its potential as a therapeutic agent. This platform provides a promising tool for drug testing and understanding resistance mechanisms, advancing personalized treatment strategies for ovarian cancer.
    Discuss this study in the Community →

    Research cited in this study

    1 / 1 results